GlassScriptPhysician profile
Robert Lynn Finney
NPI 1013208487
$18,918.01
in general payments reported to CMS, 2019-2025
27 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,421 · 2020: $4,990 · 2021: $7,632 · 2022: $1,187 · 2023: $1,207 · 2024: $1,047 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.11 |
| Education | $166.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,005.96 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $4,461.73 | 2019-2021 | |
| Galderma Laboratories, L.P. | $3,168.99 | 2019-2025 | Epsolay, Oracea, Aklief |
| Abbvie INC. | $1,049.05 | 2021-2024 | |
| Janssen Biotech, INC. | $542.50 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $516.46 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $422.21 | 2021-2025 | Winlevi, Absorica Ld |
| Merz North America, INC. | $316.84 | 2021-2023 | Xeomin |
| Lilly USA, LLC | $264.75 | 2019-2023 | Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $253.62 | 2020-2024 | Dupixent |
| Leo Pharma INC. | $244.38 | 2020-2025 | Adbry |
| Almirall LLC | $220.29 | 2021-2023 | Seysara |
| Amgen INC. | $215.67 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $186.09 | 2023-2024 | Sotyktu |
| Pfizer INC. | $181.07 | 2020-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $148.37 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $142.26 | 2024 | Zoryve |
| Journey Medical Corporation | $128.79 | 2020-2023 | |
| Epi Health, LLC | $96.00 | 2021-2022 | |
| Genzyme Corporation | $84.33 | 2021-2024 | |
| Ucb, INC. | $67.21 | 2021-2024 | Bimzelx |
| Encore Dermatology INC. | $50.13 | 2019 | |
| Dermavant Sciences, INC. | $47.98 | 2023 | Vtama |
| Incyte Corporation | $40.18 | 2025 | Opzelura |
| Dermira, INC. | $23.87 | 2019 | |
| Biofrontera INC. | $21.43 | 2021 | |
| Aclaris Therapeutics, INC. | $17.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Finney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.